ArticleESMO open2026
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.Oncology research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with pretreated metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD-TPI) + bevacizumab has superior efficacy compared with FTD-TPI alone. However, real-world data on outcomes and comparisons with other established therapies including regorafenib are scarce. Additionally, evidence suggests that molecular alterations, such as KRAS PATIENTS AND
methodsThis retrospective cohort study included 509 patients treated at six Austrian cancer centers between January 2015 and December 2022. The primary outcome was progression-free survival (PFS), with overall survival (OS) and disease control rate (DCR) as secondary outcomes. Between-group differences were analyzed using Cox and logistic regression. A propensity score analysis using inverse probability of treatment weighting (IPTW) was conducted. Flexible parametric models and restricted mean survival time (RMST) analyses were used to account for time-dependent differences in PFS/OS.
resultsIn propensity score analysis, patients treated with FTD-TPI + bevacizumab (n = 130) versus FTD-TPI (n = 227) alone or regorafenib (n = 152) had longer PFS [IPTW-adjusted hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.51-0.92, P = 0.012] and higher DCR (IPTW-adjusted odds ratio 3.35, 95% CI 1.81-6.20, P < 0.001). The IPTW-adjusted HR for OS was 0.80 (95% CI 0.58-1.12, P = 0.203). A modest OS benefit of FTD-TPI + bevacizumab was observed within the first 12 months. In RMST-analysis, OS was 12.1 months (95% CI 11.4-12.8 months) for FTD-TPI + bevacizumab compared with 10.6 months (95% CI 9.9-11.2 months) for the controls (P = 0.003). Outcomes were consistent across key molecular subsets, including KRAS and KRAS
conclusionsIn this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRAS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.